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(cont) side effects, they can still exacerbate parkinsonism.  If antipsychotic therapy is needed, quetiapine 
(Seroquel) is often well tolerated in low doses (starting with 12.5-25 mg) by PD patients.  Given their propen-
sity to develop delirium, older PD patients should not be treated with anticholinergic agents or benzodiaze-
pines, since they may trigger or exacerbate acute confusion and delirium. 
   Nonpharmacologic Interventions.  Patient with parkinsonism are prone to orthostatic hypotension, consti-
pation, urinary difficulties, falls and deconditioning.  Inpatient care should include a plan for early and daily 
mobilization with early involvement of physical and occupational therapists.  Indwelling catheters and other 
tethers should be avoided.  Nonmotor complications of PD, such as constipation, depression and orthostatic 
hypotension are generally treated as with other patients.  For patients with longstanding PD, complex medi-
cation regimens, disease complications or inability to take oral medications, early involvement of the pa-
tient’s neurologist or expert in movement disorders is advised. 
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P-ANCA Vasculitis in a Patient with Alpha-1-Antitrypsin Deficiency: A Possible Mechanism 
Introduction: 
Antineutrophil cytoplasmic antibody (ANCA) testing plays a critical role in the diagnosis and classification 
of vasculitis.  These antibodies are strongly associated with Wegener’s granulomatosis, microscopic poly-
angiitis and Churg-Strauss syndrome.  They are directed against a variety of autoantigens, including pro-
teinase 3 (PR3) and myeloperoxidase (MPO) [1].  On the other hand, alpha-1-antitrypsin (AAT) is the major 
inhibitor of PR3 while MPO is an inhibitor of AAT.  It is well known that AAT deficiency is associated with 
emphysema and liver disease.  The protein is encoded by a gene with multiple different alleles classified by 
the protease inhibitor (PI) system (PI*MM = homozygous normal, PI*ZZ = homozygous deficient).  The PI*ZZ 
phenotype carries a high risk for development of emphysema and liver disease [2].          (continued, page 3) 
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(continued) 
Case Report: 
A 50 year old white female presented with progressive myalgia involving the lower extremities, associated with 
malaise and anorexia.  She complained of bilateral jaw pain with chewing but had no abnormalities of vision.  She 
did not have cardiopulmonary or upper respiratory symptoms.  She eventually developed numbness of the lower 
extremities and a left-sided foot drop, consistent with mononeuritis multiplex.  The patient was known to be ho-
mozygous for the PP*ZZ phenotype of ATT deficiency.  However, she did not have any evidence of active lung or 
liver disease.  Her past medical history was also significant for hypothyroidism and migraines.  Family history 
was remarkable for ATT deficiency in her sister, who had both emphysema and liver cirrhosis. 
Physical exam revealed a left sided foot drop and decreased sensation to light touch distal to the knees.  No other 
neurologic deficits were identified.  Small knee effusions were evident but no rash was observed. 
Testing for p-ANCA and anti-MPO antibodies yielded positive results.  Her CRP was 48 mg/dl and her ESR was 
85mm/hr.  Temporal artery biopsy was normal.  The patient was diagnosed with ANCA associated vasculitis and 
treated with prednisone and cyclophosphamide.  Her symptoms resolved and her foot drop markedly improved 
within 6 months. 
Discussion: 
The biologic mechanisms which result in this association are unknown but it has been postulated that AAT defi-
ciency leads to increased PR3 in a pro-inflammatory environment [3,4].  On the other hand, AAT is inactivated by 
the release of myeloperoxidase from activated neutrophils.  Any mechanism that inactivates MPO would result in 
increased AAT activity.  This might mean that antibodies directed against MPO may interfere with its function 
and result in amplified AAT activity (and a lowered risk of tissue damage in AAT deficiency); this could explain 
the lack of emphysema in this patient.  In other words, it is known that patients with PI*ZZ phenotype have an 
AAT activity level that is 10-20% of normal.  Anti-MPO antibodies inhibit MPO mediated inactivation of AAT, 
resulting in higher levels of AAT activity (above the 10-20% range), which may protect against the development of 
early onset emphysema, commonly associated with the PI*ZZ phenotype. 
This case thus highlights the association between two relatively rare diseases and postulates a mechanism for this 
association.  It also helps us to understand the nature of autoimmune disease and the potential for future treat-
ment modalities. 
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